Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pilot Study on the Effects of FSH Treatment on the Epigenetic Characteristics of Spermatozoa in Infertile Patients With Severe Oligozoospermia
NCT02605070 · Instituto de Investigacion Sanitaria La Fe · PHASE3 · terminated · last registry update 2018-03-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “UNDER RECRUITMENT” | – | Registry record, Instituto de Investigacion Sanitaria La Fe |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against LHCGR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-01-14Phase 3 first posted: Centre Hospitalier Intercommunal Creteil, DUOSTIM + Conventional stimuli (NCT03803228)
- 2018-11-26Results posted on the registry: University Medical Centre Ljubljana, Elonva (NCT02606500)
- 2018-11-21Results posted on the registry: UConn Health, GnRH agonist + hCG (NCT01606709)
- 2018-11-21Also stopped (terminated): UConn Health, GnRH agonist + hCG (NCT01606709)
- 2018-11-15Phase 3 first posted: Instituto Valenciano de Infertilidad, IVI Alicante, Pre-treatment with rLH (Luveris 75 IU), (NCT03741699)
- 2018-09-14Also stopped (terminated): St. Olavs Hospital, fostimon + puregon (NCT01882166)
- 2018-08-07Also stopped (terminated): University Reproductive Associates, Luveris fixed dose + Luveris increasing dose (NCT00889512)
- 2018-08-03Results posted on the registry: Ferring Pharmaceuticals, FE 999049 + Gonal - F (NCT01426386)
- 2018-07-30Results posted on the registry: Merck KGaA, Darmstadt, Germany, r-FSH + r-hLH (NCT01112358)
- 2018-07-19Also stopped (withdrawn): University of Virginia, Hydrocortisone + dexamethasone (NCT01422733)
- 2018-04-06Results posted on the registry: Merck KGaA, Darmstadt, Germany, GONAL-f® (NCT01183143)
- 2018-03-30Results posted on the registry: Merck KGaA, Darmstadt, Germany, Gonal-f + Recombinant human chorionic gonadotrophin (r-hCG) (NCT00249834)
- 2018-03-27Results posted on the registry: Merck KGaA, Darmstadt, Germany, Recombinant human follicle stimulating hormone (r-hFSH) + Recombinant human luteinizing hormone (r-hLH) (NCT01110707)
- 2018-03-02Results posted on the registry: Ferring Pharmaceuticals, menotropin + recombinant FSH (NCT02554279)
- 2018-02-23Results posted on the registry: Wake Forest University Health Sciences, clomiphene plus gonadotropins + Leuprolide flare (NCT01921166)
- 2018-02-22Phase 3 first posted: Eastern Virginia Medical School, Progesterone Vaginal Gel 8% + Letrozole Oral Tablet (NCT03440359)
- 2018-02-06Phase 3 first posted: National and Kapodistrian University of Athens, hCG + Placebo (NCT03423537)
- 2017-11-27Phase 3 first posted: Benha University, Triptorelin SR (NCT03353883)
- 2017-10-18Results posted on the registry: Fertility Biotech AG, AFOLIA + Gonal-f® RFF (NCT01687712)
- 2017-10-17Results posted on the registry: University of California, San Diego, recombinant human chorionic gonadotropin + Recombinant human follicle stimulating hormone (NCT00989781)
- 2017-09-25Results posted on the registry: UConn Health, hCG + hCG (NCT01815138)
- 2017-05-10Also stopped (withdrawn): Mohamed Sayed Abdelhafez, Gonadotropin (NCT02458963)
- 2017-05-04Phase 3 first posted: Assiut University, Gonadotropin-Releasing Hormone Analogue + Gonadotropin releasing hormone antagonist (NCT03139474)
- 2017-03-06Phase 3 first posted: Changchun GeneScience Pharmaceutical Co., Ltd., Triptorelin for Injection + Recombinant Human Choriogonadotropin alfa Solution for Injection (NCT03071172)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision